Stevanato Group announced a significant expansion of its drug delivery systems manufacturing capacity at its Bad Oeynhausen facility in northern Germany, reinforcing the company’s global integration strategy across the pharmaceutical and biotechnology sectors.
The multi-million-dollar investment adds over 2,500 square meters of advanced production space dedicated to drug delivery devices. The upgraded site includes an ISO 8 cleanroom outfitted for injection molding and automated assembly operations, bolstering Stevanato’s capacity to deliver scalable, flexible, and high-quality self-injection and combination product solutions.
The expansion supports the manufacturing of Stevanato’s key delivery platforms, including the Aidaptus autoinjector and Alina pen injector, both designed to offer greater patient convenience and improved treatment adherence. By integrating the company’s core capabilities in glass primary packaging, analytical testing, and equipment manufacturing, the enhanced facility strengthens Stevanato’s position as a comprehensive partner for drug delivery innovation.
Michele Monico, President of the Drug Delivery Systems and In Vitro Diagnostics Business Unit, said the project underscores Stevanato Group’s commitment to advancing patient-centered self-administration technologies. “As demand for drug delivery devices accelerates, expanding our manufacturing capacity ensures readiness, agility, and innovation across the value chain,” Monico stated.